Can Moderna Repeat COVID-19 Success In Influenza Market?

First Subject Dosed In Flu Vaccine Trial

 
• By Alaric DeArment
  
Influenza A H7N9
Moderna announced that the first subject in its Phase I/II study of its mRNA influenza vaccine was dosed • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anti-infective

More from Therapy Areas